Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a newer acid blocker outperform standard care for ulcer bleeding?

NCT ID NCT07772700

Disease control Sponsor: National Cheng-Kung University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This trial tests whether a newer acid-reducing drug, vonoprazan, is better than a double dose of the standard drug esomeprazole at preventing rebleeding in people who have had a bleeding stomach or intestinal ulcer treated with endoscopy. About 108 adults at high risk of rebleeding will be randomly assigned to receive either vonoprazan once daily or esomeprazole twice daily for 28 days after initial treatment. The main goal is to see if vonoprazan reduces the chance of bleeding again within that month.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
vonoprazan (a potassium-competitive acid blocker) compared with esomeprazole (a proton pump inhibitor)
What this could lead to
If vonoprazan works better than standard therapy, it could offer a simpler, more effective way to prevent ulcer rebleeding after endoscopic treatment.
What could go wrong
This is a small, single-center trial, and the results may not apply to all patients. Vonoprazan may not be more effective than the standard treatment, and there is a risk of side effects or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 108 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Hospitalized patients \> 18 years with upper gastrointestinal ulcer bleeding, a Rockall score of 6 or higher, and treatment with endoscopic hemostasis. Exclusion Criteria: * history of hypersensitivity to PPIs or P-CABs. * non-ulcer-related bleeding, such as variceal bleeding, angiodysplasia, diverticular bleeding, diffuse mucosal bleeding, or tumor bleeding. * severe hepatic or renal impairment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bleeding are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

active peptic ulcer disease Hemorrhage hemorrhagic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bleeding

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.